About the Authors
- Derek J. Nunez
-
* E-mail: derek.j.nunez@gsk.com
Affiliation GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America
- Mark A. Bush
-
Current address: Nuventra Pharma Sciences, Durham, North Carolina, United States of America
Affiliation GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America
- David A. Collins
-
Affiliation GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America
- Susan L. McMullen
-
Affiliation GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America
- Dawn Gillmor
-
Affiliation GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America
- Glen Apseloff
-
Affiliation Ohio State University Clinical Pharmacology Unit, Columbus, Ohio, United States of America
- George Atiee
-
Affiliation Worldwide Clinical Trials, San Antonio, Texas, United States of America
- Leonor Corsino
-
Affiliation Duke University Medical Center, Durham, North Carolina, United States of America
- Linda Morrow
-
Affiliation Profil Institute for Clinical Research, Chula Vista, California, United States of America
- Paul L. Feldman
-
Affiliation GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America
Competing Interests
The authors declare the following completing interests: Derek Nunez is an employee of GlaxoSmithKline and was a stock/option holder at the time the studies were conducted. Mark Bush was an employee of GlaxoSmithKline and a stock/option holder at the time the studies were conducted. David Collins is an employee of GlaxoSmithKline and was a stock/option holder at the time the studies were conducted. Susan McMullen is an employee of GlaxoSmithKline and was a stock/option holder at the time the studies were conducted. Dawn Gillmor is an employee of GlaxoSmithKline and was a stock/option holder at the time the studies were conducted. Paul Feldman is an employee of GlaxoSmithKline and was a stock/option holder at the time the studies were conducted. Glen Apseloff is an employee of the Ohio State University and has consulted for GlaxoSmithKline. George Atiee was an employee of ICON Development Solutions at the time these studies were conducted. Leonor Corsino is an employee of the Duke University Medical Center. Linda Morrow is an employee of the Profil Institute for Clinical Research. The studies were sponsored by GlaxoSmithKline R&D. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: DJN MAB DAC SLM DG PLF. Performed the experiments: DJN MAB DAC SLM DG G. Apseloff G. Atiee LC LM. Analyzed the data: DJN MAB DAC PLF. Wrote the paper: DJN MAB DAC. Reviewed drafts and the final version of the manuscript: DJN MAB DAC SLM DG G. Apseloff G. Atiee LC LM PLF.